{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:28:52Z","timestamp":1790436532202,"version":"4.1.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008982","name":"Qatar Research Development and Innovation Council","doi-asserted-by":"publisher","award":["ARG02-0421-240249"],"award-info":[{"award-number":["ARG02-0421-240249"]}],"id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032486","name":"Qatar Research, Development and Innovation Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118620","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:27:49Z","timestamp":1769560069000},"page":"118620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Inhibiting CK2 in breast cancer: From molecular targets to drug candidates"],"prefix":"10.1016","volume":"308","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-429X","authenticated-orcid":false,"given":"Raed M.","family":"Al-Zoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2848-8698","authenticated-orcid":false,"given":"Ala'a","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8489-5873","authenticated-orcid":false,"given":"Basma","family":"Hanbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6747-9927","authenticated-orcid":false,"given":"Sally R.","family":"Al-Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1161-7244","authenticated-orcid":false,"given":"Ahmad R.","family":"Al-Qudimat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-4777","authenticated-orcid":false,"given":"Mazhar Salim","family":"Al Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4168-8548","authenticated-orcid":false,"given":"Abbas","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6748-3663","authenticated-orcid":false,"given":"Mohanad","family":"Shkoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9424-6372","authenticated-orcid":false,"given":"Asia","family":"Al Jabiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-9751","authenticated-orcid":false,"given":"Abdulilah D.","family":"Bani-Yaseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8363-1582","authenticated-orcid":false,"given":"Abdelali","family":"Agouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejmech.2026.118620_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00441-010-1068-3","article-title":"Cellular regulators of protein kinase CK2","volume":"342","author":"Montenarh","year":"2010","journal-title":"Cell Tissue Res."},{"issue":"19","key":"10.1016\/j.ejmech.2026.118620_bib2","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1093\/emboj\/20.19.5320","article-title":"Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme","volume":"20","author":"Niefind","year":"2001","journal-title":"Embo J"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118620_bib3","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/emboj\/17.9.2451","article-title":"Crystal structure of the catalytic subunit of protein kinase CK2 from Zea mays at 2.1 A resolution","volume":"17","author":"Niefind","year":"1998","journal-title":"EMBO J."},{"issue":"32","key":"10.1016\/j.ejmech.2026.118620_bib4","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.1021\/bi800216d","article-title":"The regulatory beta subunit of protein kinase CK2 contributes to the recognition of the substrate consensus sequence. A study with an eIF2 beta-derived peptide","volume":"47","author":"Poletto","year":"2008","journal-title":"Biochemistry"},{"issue":"Pt 20","key":"10.1016\/j.ejmech.2026.118620_bib5","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1242\/jcs.00074","article-title":"Protein kinase CK2: a challenge to canons","volume":"115","author":"Pinna","year":"2002","journal-title":"J. Cell Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118620_bib6","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1021\/acs.jmedchem.2c01523","article-title":"Strategies of targeting CK2 in drug discovery: challenges, opportunities, and emerging prospects","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"issue":"25","key":"10.1016\/j.ejmech.2026.118620_bib7","doi-asserted-by":"crossref","first-page":"22509","DOI":"10.1074\/jbc.M200486200","article-title":"Unique activation mechanism of protein kinase CK2. The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme","volume":"277","author":"Sarno","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118620_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1096\/fasebj.9.5.7896000","article-title":"Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation","volume":"9","author":"Allende","year":"1995","journal-title":"Faseb j."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(93)90039-G","article-title":"Casein kinases: pleiotropic mediators of cellular regulation","volume":"59","author":"Issinger","year":"1993","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118620_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1040-7952(97)80006-7","article-title":"Intrasteric regulation of protein kinases","volume":"31","author":"Kobe","year":"1997","journal-title":"Adv. Sec. Messenger Phosphoprotein. Res."},{"issue":"33","key":"10.1016\/j.ejmech.2026.118620_bib11","doi-asserted-by":"crossref","first-page":"20820","DOI":"10.1074\/jbc.272.33.20820","article-title":"Binding of polyamines to an autonomous domain of the regulatory subunit of protein kinase CK2 induces a conformational change in the holoenzyme. A proposed role for the kinase stimulation","volume":"272","author":"Leroy","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"Pt 1","key":"10.1016\/j.ejmech.2026.118620_bib12","first-page":"1","article-title":"Protein kinase CK2: structure, regulation and role in cellular decisions of life and death","volume":"369","author":"Litchfield","year":"2003","journal-title":"Biochem. J."},{"issue":"40","key":"10.1016\/j.ejmech.2026.118620_bib13","doi-asserted-by":"crossref","first-page":"12324","DOI":"10.1021\/bi0011431","article-title":"Cooperative modulation of protein kinase CK2 by separate domains of its regulatory beta-subunit","volume":"39","author":"Sarno","year":"2000","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118620_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075280","article-title":"Protein kinase CK2 inhibition down modulates the NF-\u03baB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells","volume":"8","author":"Manni","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118620_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbior.2017.03.002","article-title":"Cross-talk between the CK2 and AKT signaling pathways in cancer","volume":"64","author":"Ruzzene","year":"2017","journal-title":"Adv Biol Regul."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/biof.96","article-title":"Emergence of protein kinase CK2 as a key target in cancer therapy","volume":"36","author":"Trembley","year":"2010","journal-title":"Biofactors"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118620_bib17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molmed.2018.07.003","article-title":"An experimenter's guide to glioblastoma invasion pathways","volume":"24","author":"de Gooijer","year":"2018","journal-title":"Trends Mol. Med."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2026.118620_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11010-008-9812-7","article-title":"CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor","volume":"316","author":"Scaglioni","year":"2008","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13046-019-1292-y","article-title":"Role of protein kinase CK2 in antitumor drug resistance","volume":"38","author":"Borgo","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2017.301","article-title":"Therapeutic targeting of CK2 in acute and chronic leukemias","volume":"32","author":"Buontempo","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118620_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41389-019-0171-x","article-title":"The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells","volume":"8","author":"Di","year":"2019","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1381612822666161006154311","article-title":"Casein kinase II (CK2) as a therapeutic target for hematological malignancies","volume":"23","author":"Gowda","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bbapap.2009.07.018","article-title":"Addiction to protein kinase CK2: a common denominator of diverse cancer cells?","volume":"1804","author":"Ruzzene","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"11\u201312","key":"10.1016\/j.ejmech.2026.118620_bib24","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00018-009-9150-2","article-title":"Protein kinase CK2 in health and disease: from birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival","volume":"66","author":"St-Denis","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118620_bib25","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.18632\/oncotarget.2248","article-title":"Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells","volume":"5","author":"Gray","year":"2014","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118620_bib26","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/1078-0432.CCR-15-1314","article-title":"Molecular pathways: emergence of protein kinase CK2 (CSNK2) as a potential target to inhibit survival and DNA damage response and repair pathways in cancer cells","volume":"22","author":"Rabalski","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118620_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13058-015-0524-0","article-title":"Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy","volume":"17","author":"Kren","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"11\u201312","key":"10.1016\/j.ejmech.2026.118620_bib28","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00018-009-9154-y","article-title":"Protein kinase CK2 in health and disease: CK2: a key player in cancer biology","volume":"66","author":"Trembley","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"issue":"Pt 2","key":"10.1016\/j.ejmech.2026.118620_bib29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1042\/bj3570563","article-title":"Autocatalytic tyrosine-phosphorylation of protein kinase CK2 alpha and alpha' subunits: implication of Tyr182","volume":"357","author":"Donella-Deana","year":"2001","journal-title":"Biochem. J."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118620_bib30","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1038\/sj.onc.1205467","article-title":"Phosphorylation regulates the stability of the regulatory CK2beta subunit","volume":"21","author":"Zhang","year":"2002","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.ejmech.2026.118620_bib31","doi-asserted-by":"crossref","first-page":"18327","DOI":"10.1074\/jbc.M909736199","article-title":"Transcription factors ets1, NF-kappa B, and Sp1 are major determinants of the promoter activity of the human protein kinase CK2alpha gene","volume":"275","author":"Krehan","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118620_bib32","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1016\/S0021-9258(18)53374-3","article-title":"Human casein kinase II. The subunit alpha protein activates transcription of the subunit beta gene","volume":"268","author":"Robitzki","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118620_bib33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2009.09.034","article-title":"EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin","volume":"36","author":"Ji","year":"2009","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejmech.2026.118620_bib34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biochi.2015.12.005","article-title":"Regulation of protein kinase CK2 catalytic activity by protein kinase C and phospholipase D2","volume":"121","author":"Lee","year":"2016","journal-title":"Biochimie"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118620_bib35","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1128\/MCB.01563-08","article-title":"Evidence for regulation of mitotic progression through temporal phosphorylation and dephosphorylation of CK2alpha","volume":"29","author":"St-Denis","year":"2009","journal-title":"Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nchembio.771","article-title":"Regulation of CK2 by phosphorylation and O-GlcNAcylation revealed by semisynthesis","volume":"8","author":"Tarrant","year":"2012","journal-title":"Nat. Chem. Biol."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118620_bib37","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1093\/emboj\/cdf402","article-title":"Binding of FGF-1 variants to protein kinase CK2 correlates with mitogenicity","volume":"21","author":"Skjerpen","year":"2002","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13046-021-01848-3","article-title":"Overexpression of NELFE contributes to gastric cancer progression via Wnt\/\u03b2-catenin signaling-mediated activation of CSNK2B expression","volume":"40","author":"Yu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118620_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102603","article-title":"Tumor necrosis factor \u03b1-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-\u03baB activation in hepatocellular carcinoma","volume":"51","author":"Xiao","year":"2020","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118620_bib40","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/emboj\/18.11.2930","article-title":"Crystal structure of the human protein kinase CK2 regulatory subunit reveals its zinc finger-mediated dimerization","volume":"18","author":"Chantalat","year":"1999","journal-title":"EMBO J."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118620_bib41","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1113\/JP273883","article-title":"Angiotensin II activates Ca(V) 1.2 Ca(2+) channels through \u03b2-arrestin2 and casein kinase 2 in mouse immature cardiomyocytes","volume":"595","author":"Kashihara","year":"2017","journal-title":"J. Physiol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118620_bib42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbrc.2010.09.028","article-title":"The role of protein kinase CK2 in the regulation of the insulin production of pancreatic islets","volume":"401","author":"Meng","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.118620_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2020.101625","article-title":"miR-1184 regulates the proliferation and apoptosis of colon cancer cells via targeting CSNK2A1","volume":"53","author":"Chen","year":"2020","journal-title":"Mol. Cell. Probes"},{"issue":"15","key":"10.1016\/j.ejmech.2026.118620_bib44","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2015-06-651505","article-title":"Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia","volume":"126","author":"Song","year":"2015","journal-title":"Blood"},{"issue":"42","key":"10.1016\/j.ejmech.2026.118620_bib45","doi-asserted-by":"crossref","first-page":"32592","DOI":"10.1074\/jbc.M001358200","article-title":"Tumor necrosis factor alpha-induced phosphorylation of RelA\/p65 on Ser529 is controlled by casein kinase II","volume":"275","author":"Wang","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"11\u201312","key":"10.1016\/j.ejmech.2026.118620_bib46","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s00018-009-9153-z","article-title":"Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer","volume":"66","author":"Dominguez","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib47","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2010-01-266320","article-title":"A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway","volume":"118","author":"Zheng","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118620_bib48","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1091\/mbc.e06-07-0659","article-title":"Nuclear localization of the ERK MAP kinase mediated by Drosophila alphaPS2betaPS integrin and importin-7","volume":"18","author":"James","year":"2007","journal-title":"Mol. Biol. Cell"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118620_bib49","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3390\/ijms20051194","article-title":"Nuclear ERK: mechanism of translocation, substrates, and role in cancer","volume":"20","author":"Maik-Rachline","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118620_bib50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3389\/fonc.2020.00893","article-title":"Protein kinase CK2 in cancer energetics","volume":"10","author":"Silva-Pavez","year":"2020","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118620_bib51","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1210\/en.2008-0351","article-title":"ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer cells","volume":"149","author":"Taylor","year":"2008","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/sigtrans.2017.29","article-title":"The emerging role of zinc transporters in cellular homeostasis and cancer","volume":"2","author":"Bafaro","year":"2017","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118620_bib53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12974-015-0470-x","article-title":"Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology","volume":"13","author":"Rosenberger","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"18","key":"10.1016\/j.ejmech.2026.118620_bib54","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.3390\/ijms20184398","article-title":"Protein kinase CK2-A putative target for the therapy of diabetes mellitus?","volume":"20","author":"Ampofo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118620_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neulet.2018.08.021","article-title":"CK2 inhibition protects white matter from ischemic injury","volume":"687","author":"Baltan","year":"2018","journal-title":"Neurosci. Lett."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118620_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115609","article-title":"Mining CK2 in cancer","volume":"9","author":"Ortega","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2020.07.001","article-title":"Kinase interaction network expands functional and disease roles of human kinases","volume":"79","author":"Buljan","year":"2020","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib58","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbapap.2009.11.001","article-title":"Regulation of cell proliferation and survival: convergence of protein kinases and caspases","volume":"1804","author":"Duncan","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"47","key":"10.1016\/j.ejmech.2026.118620_bib59","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.1038\/onc.2016.86","article-title":"Targeting CK2-driven non-oncogene addiction in B-cell tumors","volume":"35","author":"Mandato","year":"2016","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118620_bib60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.17219\/acem\/37040","article-title":"Protein kinase CK2 and angiogenesis","volume":"23","author":"Montenarh","year":"2014","journal-title":"Adv. Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118620_bib61","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF03401606","article-title":"Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck","volume":"1","author":"Gapany","year":"1995","journal-title":"Mol Med"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118620_bib62","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1016\/j.ajpath.2016.08.007","article-title":"CK2\u03b1\/CSNK2A1 phosphorylates SIRT6 and is involved in the progression of breast carcinoma and predicts shorter survival of diagnosed patients","volume":"186","author":"Bae","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/ijerph13010036","article-title":"Protein kinase CK2 expression predicts relapse survival in ER\u03b1 dependent breast cancer, and modulates ER\u03b1 expression in vitro","volume":"13","author":"Williams","year":"2015","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa063994","article-title":"The prognostic role of a gene signature from tumorigenic breast-cancer cells","volume":"356","author":"Liu","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118620_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076247","article-title":"miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-\u03b1, CCNJ, and MEGF9","volume":"8","author":"Feliciano","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118620_bib66","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1038\/sj.onc.1204411","article-title":"Protein kinase CK2 in mammary gland tumorigenesis","volume":"20","author":"Landesman-Bollag","year":"2001","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118620_bib67","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1432-1033.1990.tb15484.x","article-title":"Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue","volume":"189","author":"M\u00fcnstermann","year":"1990","journal-title":"Eur. J. Biochem."},{"issue":"25","key":"10.1016\/j.ejmech.2026.118620_bib68","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1038\/sj.onc.1204411","article-title":"Protein kinase CK2 in mammary gland tumorigenesis","volume":"20","author":"Landesman-Bollag","year":"2001","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118620_bib69","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/01926230500352226","article-title":"Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors","volume":"33","author":"Currier","year":"2005","journal-title":"Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib70","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cbic.200600293","article-title":"Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors","volume":"8","author":"Pagano","year":"2007","journal-title":"Chembiochem"},{"issue":"29","key":"10.1016\/j.ejmech.2026.118620_bib71","doi-asserted-by":"crossref","first-page":"22245","DOI":"10.1074\/jbc.M002446200","article-title":"Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein","volume":"275","author":"Ford","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118620_bib72","series-title":"Protein Kinase CK2","first-page":"363","article-title":"Role of CK2 in the control of cell plasticity in breast carcinoma progression","author":"Filhol","year":"2013"},{"issue":"24","key":"10.1016\/j.ejmech.2026.118620_bib73","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","article-title":"CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy","volume":"70","author":"Siddiqui-Jain","year":"2010","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118620_bib74","doi-asserted-by":"crossref","first-page":"11375","DOI":"10.1158\/0008-5472.CAN-05-1602","article-title":"Inducible IkappaB kinase\/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells","volume":"65","author":"Eddy","year":"2005","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118620_bib75","first-page":"4008","article-title":"Alterations of microRNAs are associated with impaired growth of MCF-7 breast cancer cells induced by inhibition of casein kinase 2","volume":"7","author":"Li","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118620_bib76","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cellsig.2016.03.007","article-title":"Estrogen receptor alpha transcriptionally activates casein kinase 2 alpha: a pivotal regulator of promyelocytic leukaemia protein (PML) and AKT in oncogenesis","volume":"28","author":"Das","year":"2016","journal-title":"Cell. Signal."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118620_bib77","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1128\/MCB.01246-10","article-title":"ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells","volume":"31","author":"Hagan","year":"2011","journal-title":"Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib78","first-page":"313","article-title":"Characterization and hormonal regulation of casein kinase II activity in heterotransplanted human breast tumors in nude mice","volume":"90","author":"McManaway","year":"1987","journal-title":"Exp. Clin. Endocrinol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118620_bib79","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lfs.2013.12.009","article-title":"Premature senescence in human breast cancer and colon cancer cells by tamoxifen-mediated reactive oxygen species generation","volume":"97","author":"Lee","year":"2014","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118620_bib80","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2007.06.010","article-title":"Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT","volume":"256","author":"Yde","year":"2007","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1084\/jem.99.3.227","article-title":"Inhibition of influenza virus multiplication by N-glycosides of benzimidazoles-N","volume":"99","author":"Tamm","year":"1954","journal-title":"J. Exp. Med."},{"issue":"Pt 3","key":"10.1016\/j.ejmech.2026.118620_bib82","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1042\/bj20030674","article-title":"Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA)","volume":"374","author":"Sarno","year":"2003","journal-title":"Biochem. J."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118620_bib83","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1016\/S0021-9258(17)35799-X","article-title":"Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription","volume":"261","author":"Zandomeni","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1432-1033.1990.tb15280.x","article-title":"Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1","volume":"187","author":"Meggio","year":"1990","journal-title":"Eur. J. Biochem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib85","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1006\/bbrc.1995.1354","article-title":"Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources","volume":"208","author":"Szyszka","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118620_bib86","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1110\/ps.19601","article-title":"Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole","volume":"10","author":"Battistutta","year":"2001","journal-title":"Protein Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib87","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0014-5793(01)02404-8","article-title":"Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2')","volume":"496","author":"Sarno","year":"2001","journal-title":"FEBS Lett."},{"issue":"Pt 1","key":"10.1016\/j.ejmech.2026.118620_bib88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1042\/bj3640041","article-title":"Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells","volume":"364","author":"Ruzzene","year":"2002","journal-title":"Biochem. J."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2026.118620_bib89","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11010-008-9827-0","article-title":"New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole","volume":"316","author":"Bretner","year":"2008","journal-title":"Mol. Cell. Biochem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118620_bib90","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.bbapap.2013.01.018","article-title":"Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases","volume":"1834","author":"Cozza","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"16","key":"10.1016\/j.ejmech.2026.118620_bib91","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1007\/s00018-013-1552-5","article-title":"Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential","volume":"71","author":"Cozza","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118620_bib92","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bbrc.2004.07.067","article-title":"2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2","volume":"321","author":"Pagano","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2026.118620_bib93","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.seminoncol.2018.04.006","article-title":"CIGB-300: a peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation","volume":"45","author":"Perea","year":"2018","journal-title":"Semin. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib94","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1042\/BJ20080309","article-title":"The selectivity of inhibitors of protein kinase CK2: an update","volume":"415","author":"Pagano","year":"2008","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118620_bib95","first-page":"15","article-title":"Tenfibgen-DMAT nanocapsule delivers CK2 inhibitor DMAT to prostate cancer xenograft tumors causing inhibition of cell proliferation","volume":"6","author":"Trembley","year":"2014","journal-title":"Mol. Cell. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib96","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/mol.112.078295","article-title":"Casein kinase 2\u03b1 regulates multidrug resistance-associated protein 1 function via phosphorylation of Thr249","volume":"82","author":"Stolarczyk","year":"2012","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118620_bib97","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/pharmaceutics15071991","article-title":"Synthesis and anticancer activity of novel dual inhibitors of human protein kinases CK2 and PIM-1","volume":"15","author":"Wi\u0144ska","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib98","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/ph10010026","article-title":"The development of CK2 inhibitors: from traditional pharmacology to in Silico rational drug design","volume":"10","author":"Cozza","year":"2017","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau9060","article-title":"Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth","volume":"5","author":"Oshima","year":"2019","journal-title":"Sci. Adv."},{"issue":"39","key":"10.1016\/j.ejmech.2026.118620_bib100","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.1021\/bi2008382","article-title":"Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer","volume":"50","author":"Battistutta","year":"2011","journal-title":"Biochemistry"},{"issue":"19","key":"10.1016\/j.ejmech.2026.118620_bib101","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1016\/j.bmc.2015.08.006","article-title":"Kinase Hinge binding scaffolds and their hydrogen bond patterns","volume":"23","author":"Xing","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118620_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112770","article-title":"Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor","volume":"208","author":"Kr\u00e4mer","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118620_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2020.12.013","article-title":"Development of a potent and selective chemical probe for the pleiotropic kinase CK2","volume":"28","author":"Wells","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118620_bib104","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/kinasesphosphatases1040017","article-title":"CK2 chemical probes: past, present, and future","volume":"1","author":"Ong","year":"2023","journal-title":"Kinases and Phosphatases"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118620_bib105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/yea.3230","article-title":"Emodin, a natural inhibitor of protein kinase CK2, suppresses growth, hyphal development, and biofilm formation of Candida albicans","volume":"34","author":"Janeczko","year":"2017","journal-title":"Yeast"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-1999-13953","article-title":"Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor","volume":"65","author":"Yim","year":"1999","journal-title":"Planta Med."},{"issue":"40","key":"10.1016\/j.ejmech.2026.118620_bib107","doi-asserted-by":"crossref","first-page":"12931","DOI":"10.1021\/bi048999g","article-title":"Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study","volume":"43","author":"Meggio","year":"2004","journal-title":"Biochem"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib108","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1074\/jbc.M209367200","article-title":"Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight","volume":"278","author":"De Moliner","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib109","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1042\/BJ20090069","article-title":"Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2","volume":"421","author":"Cozza","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.118620_bib110","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/734127","article-title":"The selectivity of CK2 inhibitor quinalizarin: a reevaluation","volume":"2015","author":"Cozza","year":"2015","journal-title":"BioMed Res. Int."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118620_bib111","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1039\/C6SC02335E","article-title":"Specific inhibition of CK2\u03b1 from an anchor outside the active site","volume":"7","author":"Brear","year":"2016","journal-title":"Chem. Sci."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118620_bib112","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.bmc.2017.04.037","article-title":"A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066","volume":"25","author":"De Fusco","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118620_bib113","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1039\/C7SC05122K","article-title":"Second-generation CK2\u03b1 inhibitors targeting the \u03b1D pocket","volume":"9","author":"Iegre","year":"2018","journal-title":"Chem. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118620_bib114","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1021\/acs.jmedchem.1c00063","article-title":"Molecular plasticity of Crystalline CK2\u03b1' leads to KN2, a bivalent inhibitor of protein kinase CK2 with extraordinary selectivity","volume":"65","author":"Lindenblatt","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118620_bib115","article-title":"AB668, a novel highly selective protein kinase CK2 inhibitor with a distinct anti-tumor mechanism as compared to CX-4945 and SGC-CK2-1","author":"Bancet","year":"2022","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118620_bib116","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1021\/jm101251q","article-title":"Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer","volume":"54","author":"Pierre","year":"2011","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118620_bib118","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1359-6349(10)72121-2","article-title":"414 clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: interim report from the phase 1 clinical trial","volume":"8","author":"Padgett","year":"2010","journal-title":"European Journal of Cancer Supplements"},{"key":"10.1016\/j.ejmech.2026.118620_bib119","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fphar.2015.00070","article-title":"The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies","volume":"6","author":"Chon","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbrc.2011.10.046","article-title":"Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer","volume":"415","author":"Drygin","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118620_bib121","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3390\/cancers16142501","article-title":"Silmitasertib (CX-4945) disrupts ER\u03b1\/HSP90 interaction and drives proteolysis through the disruption of CK2\u03b2 function in breast cancer cells","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.118620_bib122","unstructured":"Studies of Silmitasertib (CX-4945). ClinicalTrials.gov: Search results for CX-4945 https:\/\/clinicaltrials.gov\/search?intr=CX-4945."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118620_bib123","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/hep.32804","article-title":"Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced\/metastatic cholangiocarcinoma: a Phase 1b\/2 study","volume":"77","author":"Borad","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2026.118620_bib124","unstructured":"Phase I Study of CX-4945 (Silmitasertib) in Basal Cell Carcinoma (NCT03897036. ASCO Annual Meeting. p. TPS1008."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118620_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094978","article-title":"Identification of a novel function of CX-4945 as a splicing regulator","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118620_bib126","first-page":"839","article-title":"A chemical with proven clinical safety rescues down-syndrome-related phenotypes in through DYRK1A inhibition","volume":"9","author":"Kim","year":"2016","journal-title":"Dis. Model. Mech."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118620_bib127","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1021\/acs.jmedchem.1c00131","article-title":"Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine derivatives as highly selective CK2 inhibitors with potent cancer cell stemness inhibition","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118620_bib128","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1021\/acsmedchemlett.2c00530","article-title":"Discovery of a potent and selective naphthyridine-based chemical probe for Casein Kinase 2","volume":"14","author":"Davis-Gilbert","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2026.118620_bib129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11010-008-9814-5","article-title":"CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo","volume":"316","author":"Perea","year":"2008","journal-title":"Mol. Cell. Biochem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118620_bib130","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/biomedicines9070766","article-title":"Targeting of protein kinase CK2 in acute Myeloid leukemia cells using the clinical-grade synthetic-peptide CIGB-300","volume":"9","author":"Rosales","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118620_bib131","first-page":"1","article-title":"Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization","volume":"10","author":"MF","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118620_bib132","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2016.05.026","article-title":"CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models","volume":"107","author":"Benavent Acero","year":"2017","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118620_bib133","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41392-021-00567-7","article-title":"Protein kinase CK2: a potential therapeutic target for diverse human diseases","volume":"6","author":"Borgo","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118620_bib134","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1471-2407-9-146","article-title":"Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies","volume":"9","author":"Solares","year":"2009","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118620_bib135","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.chembiol.2020.12.013","article-title":"SGC-CDevelopment of a potent and selective chemical probe for the pleiotropic kinase CK2","volume":"28","author":"Wells","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"40","key":"10.1016\/j.ejmech.2026.118620_bib136","doi-asserted-by":"crossref","first-page":"12931","DOI":"10.1021\/bi048999g","article-title":"Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study","volume":"43","author":"Meggio","year":"2004","journal-title":"Biochemistry"},{"issue":"15_suppl","key":"10.1016\/j.ejmech.2026.118620_bib140","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1200\/jco.2011.29.15_suppl.3087","article-title":"Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2","volume":"29","author":"Marschke","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3_suppl","key":"10.1016\/j.ejmech.2026.118620_bib138","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.2021.39.3_suppl.312","article-title":"Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: a phase Ib\/II study","volume":"39","author":"Borad","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118620_bib141","doi-asserted-by":"crossref","first-page":"163","DOI":"10.14312\/2052-4994.2013-25","article-title":"Pharmacological and safety evaluation of CIGB-300, a casein kinase 2 inhibitor peptide, administered intralesionally to patients with cervical cancer stage IB2\/II","volume":"1","author":"Soriano","year":"2013","journal-title":"J. Cancer Res. Therapeut."},{"issue":"15_suppl","key":"10.1016\/j.ejmech.2026.118620_bib137","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1200\/jco.2011.29.15_suppl.3087","article-title":"Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2","volume":"29","author":"Marschke","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118620_bib139","doi-asserted-by":"crossref","first-page":"163","DOI":"10.14312\/2052-4994.2013-25","article-title":"Pharmacological and safety evaluation of CIGB-300, a casein kinase 2 inhibitor peptide, administered intralesionally to patients with cervical cancer stage IB2\/II","volume":"1","author":"Soriano","year":"2013","journal-title":"Journal of Cancer Research & Therapy"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:07:56Z","timestamp":1779743276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":140,"alternative-id":["S0223523426000656"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118620","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibiting CK2 in breast cancer: From molecular targets to drug candidates","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118620"}}